Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review

ConclusionAccording to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors.Trial registrationThis study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).
Source: Heart Failure Reviews - Category: Cardiology Source Type: research